title: [Prophylactic effects of magnesium sulfate and ligustrazin on the hypoxic-ischemic brain damage in neonatal rats].
abstract: OBJECTIVE
  A model in neonatal rats was established to study pathophysiology of perinatal hypoxic-ischemic brain damage.
  
  
  METHODS
  7-9 day old Wistar rats were subjected to unilateral carotied artery ligation followed by hypoxic state for 3 hours (10% O2 + 90% N2, at 37 degrees C). Magnesium sulfate (0.5 mg/gBW) and ligustrazin (0.1 mg/gBW) was separately given a 30 min before hypoxia. Superoxide dismutase (SOD) and malonic dialdehyde (MDA) in the cerebral cortex and serum MDA were measured immediately after hypoxia. Neuropathologic examination was made in 4 weeks after hypoxia.
  
  
  RESULTS
  It was found that SOD and MDA in the cerebral cortex and serum MDA in the hypoxicischemic group were significantly increased in comparision with the normal control group (P < 0.01), and that all these parameters either in the magnesium sulfate group or in the ligustrazin group were lower than in the hypoxic-ischemic group (P < 0.05). The hypoxic-ischemic group showed that there were neuronal degenerations in the gray matter, hippocampus and cerebellum which were reduced in the two treatment groups.
  
  
  CONCLUSIONS
  Our results indicate that oxide free radical formation is one of the pathogenic factors of perinatal hypoxic-ischemic brain damage and magnesium sulfate and ligustrazin reduce hypoxicischemic brain damage due to indirect anti-oxidation.
authors.affiliation: PUMC Hospital, Beijing.
authors.forename: D
authors.initials: D
authors.lastname: Wang
authors.forename: H
authors.initials: H
authors.lastname: Zhang
authors.forename: S
authors.initials: S
authors.lastname: Zhao
authors.forename: M
authors.initials: M
authors.lastname: Wei
authors.forename: H
authors.initials: H
authors.lastname: Zhang
mesh_terms: D000818:Animals; D000831:Animals, Newborn; D002545:Brain Ischemia / Q000378:metabolism / Q000517:prevention & control*; D002121:Calcium Channel Blockers / Q000494:pharmacology*; D002540:Cerebral Cortex / Q000378:metabolism / Q000473:pathology; D005260:Female; D000860:Hypoxia / Q000150:complications; D008278:Magnesium Sulfate / Q000494:pharmacology*; D008297:Male; D008315:Malondialdehyde / Q000378:metabolism; D009474:Neurons / Q000473:pathology; D011719:Pyrazines / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D013482:Superoxide Dismutase / Q000378:metabolism
chemical_list: D002121:Calcium Channel Blockers; D011719:Pyrazines; D008315:Malondialdehyde; D008278:Magnesium Sulfate; D013482:Superoxide Dismutase; C017953:tetramethylpyrazine